Search for NPC clues could speed future treatments
NCT ID NCT00344331
First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 11 times
Summary
This study aims to find biological markers that can track the progression of Niemann-Pick type C (NPC), a rare genetic disorder that damages the nervous system. Researchers will evaluate 900 patients of any age through regular checkups, spinal taps, eye exams, and brain scans. The goal is to identify reliable measures for use in future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify reliable ways to measure NPC progression, making future treatment trials faster and more accurate.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear markers, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NIEMANN-PICK DISEASE, TYPE C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for rare brain disorders in early trial
- Hope for rare brain disease: new drug trial targets movement and daily life
- Promising drug tested for rare liver disease in newborns
- Scientists dive into rare cholesterol disorders to uncover clues
- New study aims to crack the code of rare brain disease
- New york program offers extra screening for 100,000 newborns